The “Next Bitcoin”? 10 CENT Crypto Set to Explode

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Chrystal Menard Biography and Net Worth

Insider of Cerus

Ms. Menard was appointed Chief Legal Officer in 2012. Prior to joining Cerus, Ms. Menard served as senior corporate counsel at Zynga, Inc. From 2000-2011, she was a partner at Cooley LLP, where she had practiced corporate and securities law. Ms. Menard received her Juris Doctorate from the University of Chicago and her Bachelor of Science in finance and accounting from the University of Colorado, Boulder.

What is Chrystal Menard's net worth?: The estimated net worth of Chrystal Menard is at least $579,041.91 as of March 13th, 2023. Ms. Menard owns 338,621 shares of Cerus stock worth more than $579,042 as of April 28th. This net worth approximation does not reflect any other assets that Ms. Menard may own. Learn More about Chrystal Menard's net worth.
How do I contact Chrystal Menard?: The corporate mailing address for Ms. Menard and other Cerus executives is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. Cerus can also be reached via phone at (925) 288-6000 and via email at [email protected]. Learn More on Chrystal Menard's contact information.
Has Chrystal Menard been buying or selling shares of Cerus?: Chrystal Menard has not been actively trading shares of Cerus during the last ninety days. Most recently, Chrystal Menard sold 15,468 shares of the business's stock in a transaction on Monday, March 13th. The shares were sold at an average price of $2.80, for a transaction totalling $43,310.40. Following the completion of the sale, the insider now directly owns 338,621 shares of the company's stock, valued at $948,138.80. Learn More on Chrystal Menard's trading history.
Who are Cerus' active insiders?: Cerus' insider roster includes Laurence Corash (Insider), Kevin Green (CFO), William Greenman (CEO), Vivek Jayaraman (COO), Chrystal Menard (Insider), Carol Moore (SVP), Gail Schulze (Director), and Daniel Swisher, Jr. (Director). Learn More on Cerus' active insiders.
Are insiders buying or selling shares of Cerus?: In the last year, Cerus insiders bought shares 3 times. They purchased a total of 22,500 shares worth more than $38,875.00. In the last year, insiders at the biotechnology company sold shares 6 times. They sold a total of 177,516 shares worth more than $372,911.99. The most recent insider tranaction occured on March, 14th when CFO Kevin Dennis Green sold 21,497 shares worth more than $42,349.09. Insiders at Cerus own 7.1% of the company. Learn More about insider trades at Cerus.
Information on this page was last updated on 3/14/2024.

Chrystal Menard Insider Trading History at Cerus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2023	Sell	15,468	$2.80	$43,310.40	338,621
11/3/2021	Sell	40,000	$7.70	$308,000.00
2/8/2021	Sell	8,125	$8.00	$65,000.00	52,752
12/22/2020	Sell	211,327	$8.00	$1,690,616.00	134,001
12/11/2020	Sell	41,363	$8.00	$330,904.00	52,742
8/7/2020	Sell	23,621	$7.07	$167,000.47	48,585
5/12/2020	Sell	20,351	$5.67	$115,390.17	72,206
3/17/2020	Sell	26,535	$3.59	$95,260.65	7,500
3/12/2018	Sell	1,960	$4.80	$9,408.00	4,832

Chrystal Menard Buying and Selling Activity at Cerus

Cerus Company Overview

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Today's Range

Now: $1.71

$1.67

$1.72

50 Day Range

MA: $1.95

$1.64

$2.42

2 Week Range

Now: $1.71

$1.21

$3.08

Volume

387,036 shs

Average Volume

900,610 shs

Market Capitalization

$309.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

The “Next Bitcoin”? 10 CENT Crypto Set to Explode

From True Market Insiders | Ad